Stage Migration of Metastatic Malignant Cutaneous Melanoma by $^{18}\text{F}-\text{FDG}$ PET-CT Scan- A Case Report

FatemaTuz Zohra, Azmal Kabir Sarker, Juwel Hosen, Md. Khairul Islam, Rahima Akter Sharmin, Md. Jakir Hosen, Rayhan Alam, Md. Abul Hasnat, M Monjur Ahasan

1Institute of Nuclear Medical Physics, AERE, Savar, Dhaka 1349
2Institute of Nuclear Medicine and Allied Sciences, Mitford, Dhaka 1100

Correspondence Address: Dr. FatemaTuz Zohra, Institute of Nuclear Medical Physics, AERE, Savar, Dhaka 1349
Email: zohra.baec@gmail.com

ABSTRACT

$^{18}\text{F}$-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) often causes stage migration that in turn facilitates management strategy of the diseases. This case report is an excision biopsy proven case of malignant cutaneous melanoma (malignant CM) stage pT3aN3b with clinico-pathological stage IIIC disease that was restaged to pT3aN3cM1b or stage IV disease after an $^{18}\text{F}$-FDG PET-CT scan and completely changed the therapeutic approaches. Utilization of pre therapeutic $^{18}\text{F}$-FDG PET-CT ensures appropriate staging and aids in adoption of stage appropriate management in malignant CM.

Key words: Metastatic, Malignant cutaneous melanoma, $^{18}\text{F}$-FDG, PET-CT.

INTRODUCTION

Avasc Over the past few decades $^{18}$F-fluorodeoxyglucose (FDG) PET-CT is increasingly being found superior to other imaging modalities for staging of metastatic cutaneous melanoma (CM) resulting in stage migration and change of management (1,2). Though melanoma is less prevalent in Southeast Asia, $^{18}$F-fluorodeoxyglucose (FDG) PET-CT imaging is being regularly practiced in Bangladesh for the staging and management (3). The combination of functional and morphologic imaging using the new advanced dual modality PET-CT is supposed to provide superior performance in overall TNM staging of various oncologic diseases. It is considered to be significantly more accurate than CT or PET alone (4,5). Detection of $^{18}$F-FDG avid subcutaneous metastasis in malignant melanoma has prognostic implication and can help not only to restage the disease but also to guide new therapeutic strategies. The use of PET-CT is a possible first-line modality for detection and differentiation of metastases in areas inaccessible by physical examination or biopsy (6).

CASE REPORT

A 66 years old female initially presented with a solid, firm small mass in her left sole of the foot and underwent excision biopsy, which, on histopathology revealed malignant CM (stage T3a). She was found to have inguinal lymphadenopathy which was cytologically proven as nodal metastasis of stage N3. With clinico-pathological stage IIIC disease, she underwent $^{18}$F-fluorodeoxyglucose (FDG) PET-CT scan for exclusion of distant metastasis. Whole body PET-CT scan (from vertex to toe) was performed with 5 mCi intravenous administration of $^{18}$F-FDG after proper preparation with Philips 128 slice ingenuity TF following the standard protocol using no contrast.

There were multiple hypermetabolic (SUVmax up to 13.5) metastatic subcutaneous nodules throughout the left lower limb along the course of great saphenous vein (Figure 1).

Figure 1: Whole body $^{18}$F-FDG PET-CT images of Maximum Intensity Projection (MIP) view (left) and coronal view (right) showing hypermetabolic nodules in left lower limb.
Multiple conglomerated hypermetabolic (SUVmax 13.0) lymph nodes were found in left inguino-femoral regions (Figure 2).

![Figure 2: Axial images of 18F-FDG PET-CT scan, showing hypermetabolic left inguino-femoral lymph nodes (A, B).](image1)

Soft tissue density areas (up to 14 mm with HU 57) with hypermetabolism (SUVmax 19.0) were noted in posterior and medial aspect of left psoas muscle at the level of 5th lumbar vertebra (Figure 3).

![Figure 3: Axial CT image (A) showing soft tissue density mass and fused axial view (B) showing hypermetabolic activity in the mass at the medial aspect of left psoas muscle.](image2)

Multiple (at least three) hypermetabolic (SUVmax up to 10.6) nodules with diameter of up to 13 mm in right lung, (Figure 4, A-B) and a 15 mm hypermetabolic (SUVmax 5.4) right hilar lymph node (Figure 4, C-D)
DISCUSSION

The reported global incidence of melanoma in 2015 was more than 5 cases per 100 thousand while its estimated incidence in Bangladesh was 1.1 with mortality rate of 0.3 (3). Worldwide, the incidence of CM is higher with poorer survival rate after 6th decade of life compared to those in younger (7-9). While there has been improvement in survival in the last few decades, but the survival still remains poor as the disease stage advances (8).

Melanoma cells uptake high volume of glucose analog 18F-fluorodeoxyglucose (18F-FDG). This high 18F-FDG uptake and the disputable metastatic spread of malignant melanoma are best conditions for functional metabolic imaging with whole body 18F-FDG PET-CT scan (2). Reinhardt MJ et al. showed the most significant advantage of combined PET-CT imaging in comparison to the single modalities was an improved detection and differentiation of distant metastases, especially of visceral metastases (6).

Up to 31% of patients with CM can present with stage IV disease at initial diagnosis (10). 18F-FDG PET-CT is recommended for baseline evaluation, surveillance and prognostication of AJCC stage III and IV malignant CM (11,12) by virtue of its proven superiority compared to other imaging modalities in terms of sensitivity and specificity. 18F-FDG PET-CT causes stage migration in 34% (1) and change of management effect in 26% (2). For regional staging, study showed better accuracy of PET in Stage III melanoma compared with Stage I and II disease (13).

18F-FDG PET-CT is useful for detection of centimetric or larger sized metastatic CM in deep soft-tissue, lymph node, lung, liver or brain (14). Identification of nodal metastasis and isolated metastases in brain or lung by 18F-FDG PET-CT can guide metastatectomy leading to improvement of survival in metastatic CM (2,15). In this case, metastatectomy was refrained because of the patient’s age and associated ischemic heart disease. Cardiac arrhythmia (16) and greater lesion size (17) are risk factors for increased morbidity in elderly patients.

The 5-year survival for stage IV CM is 15-20% (4). Median survival rate with pulmonary metastases is 7.3 months that further declines to less than seven months in patients with metastases in other visceral sites. The treatment of metastatic CM with chemotherapy has a response rate of 20% with single agents and 40% with combination agent. Recent trend of management also include surgery, radiation therapy, interferon, interleukin-2, vaccines, and gene transfer therapy (18).

Lung has remained the most common site of involvement with reported proportion of up to 36% of
cases with visceral metastasis from malignant CM (10). This constitutes about 5% of all secondary pulmonary malignancies (19). The common manifestation of thoracic metastasis of malignant CM have been described as multiple (40%) or solitary (20%) pulmonary nodules while the rare forms include miliary pattern, mediastinal lymphadenopathy, pleural effusions, lytic bone lesions and extra-pleural mass (20).

CONCLUSION

18F-FDG PET-CT has an important role in restaging of metastatic malignant CM that aided oncologist to administer stage appropriate regimen of chemotherapy.

REFERENCES

1. Eigtved A, Andersson AP, Dahlström K, Rabøl A, Jensen M, Holm S, Sørensen SS, Drzewiecki KT, Hojgaard L, Friberg L. Use of fluorine-18 fluoro-deoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. European journal of nuclear medicine. 2000 Jan 1;27(1):70-5.

2. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the 18F-FDG PET literature. J Nucl Med 2001;42(5 suppl):1S-93S.PMID: 11884507

3. Karimkhani C, Green AC, Nijsten T, Weinstock MA, Dellavalle RP, Naghavi M et al. The global burden of melanoma: results from the Global Burden of Disease Study 2015. Br J Dermatol. 2017;177(1):134-40. doi: 10.1111/bjd.15510.

4. Antoch G, Vogt FM, Freundenberg LS, Nazaradeh F, Goehe SC, Barkhausen J, Dahmen G, Bockisch A, Debatin JF, Ruehm SG. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. Jama. 2003 Dec 24;290(24):3199-206.doi:10.1001/jama.290.24.3199

5. Antoch G, Saoudi N, Kuehl H, Dahmen G, Mueller SP, Beyer T, Bockisch A, Debatin JF, Freundenberg LS. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (18F-FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. Journal of Clinical Oncology. 2004 Nov 1;22(21):4357-68.DOI: 10.1200/JCO.2004.08.120

6. Reinhardt MJ, Joe AY, Jaeger U, Huber A, Matthies A, Bucerius J, Roedel R, Strunk H, Bieber T, Biersack HJ, Tüting T. Diagnostic performance of whole body dual modality 18F-18F-FDG PET/CT imaging for N-and M-staging of malignant melanoma: experience with 250 consecutive patients. Journal of clinical oncology. 2006 Mar 1;24(7):1178-87.DOI: 10.1200/JCO.2005.03.5634

7. Key Statistics for Melanoma Skin Cancer [Internet]. Cancer.org. 2019 [cited 15 August 2019]. Available from: https://www.cancer.org/cancer/melanoma-skin-cancer/about/key-statistics.html

8. Melanoma skin cancer statistics [Internet]. Cancer Research UK. 2019 [cited 15 August 2019]. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/melanoma-skin-cancer#heading

9. Melanoma facts and statistics - Melanoma Institute Australia [Internet]. Melanoma Institute Australia. 2019 [cited 15 August 2019]. Available from: https://www.melanoma.org.au/understanding-melanoma/melanoma-facts-and-statistics/

10. Tas F. Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors. J Oncol. 2012;2012:647684. doi: 10.1155/2012/647684.

11. Gallamini A, Zwarthoed C, Borra A. Positron Emission Tomography (PET) in Oncology. Cancers (Basel) 2014;6(4)1821-89 DOI: 10.3390/cancers6041821

12. [No authors listed]. Melanoma, version 2.2011. In: NCCN clinical practice guidelines in oncology. Fort Washington, PA: National Comprehensive Cancer Network, 2011

13. Mijnhout GS, Hoekstra OS, van Tulder MW, Teule GJ, Devillé WL. Systematic review of the diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in melanoma patients. Cancer 2001;91(8):1530-42.DOI: 10.1002/1097-0142(20010415)91:8

14. Chatziioannou SN. The Role of PET scan in melanoma management. Melanoma Research 2010; 20(p):e10. DOI: 10.1097/01.cmr.0000382764.23990.da

15. Schuhan C, Muley T, Dienemann H, Pfannschmidt J. Survival after pulmonary metastasectomy in patients with malignant melanoma. ThoracCardiovasc Surg. 2011;59(3):158-62. doi: 10.1055/s-0030-1250669.

16. Hanna TP, Chauvin C, Miao Q, Rizkalla M, Reid K, Peng Y et al. Clinical Outcomes After Pulmonary Metastasectomy for Melanoma: A Population-Based Study. Ann Thorac Surg. 2018;106(6):1675-81. doi: 10.1016/j.athoracsur.2018.06.0

17. Ho RC. Medical management of stage IV malignant melanoma. Medical issues. Cancer. 1995;75(2):735-41. DOI: 10.1002/1097-0142(19950115)75:2

18. Libshitz HI, North LB. Pulmonary metastases. RadiolClin North Am. 1982; 20(3):437-51.PMID: 7117101

19. Sponholz S, Sørensen SS, Drzewiecki KT, Højgaard L, Friberg L. Use of fluorine-18 fluoro-deoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. European journal of nuclear medicine. 2000 Jan 1;27(1):70-5.

20. Chen JT, Dahmash NS, Ravin CE, Heaston DK, Putman CE, Seigler HF et al. Metastatic melanoma in the thorax: report of 130 patients. AJR 1981;137:293-8. DOI: 10.2214/ajr.137.2.293